Alembic Pharma Q3: Cons (YoY)

Net Profit Down 67.8% At Rs 86.5 Cr Vs Rs 269 Cr;

Revenue Down 16.9% At Rs 777 Cr Vs Rs 931 Cr

EBITDA Down 62.1% At Rs 145.4 Cr Vs Rs 384 Cr;

EBITDA Margin At 18.7% Vs 41.2%